<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="152875">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01699490</url>
  </required_header>
  <id_info>
    <org_study_id>NSC 101-2314-B-006 -064 -MY3</org_study_id>
    <nct_id>NCT01699490</nct_id>
  </id_info>
  <brief_title>Role of Inflammation Factors and Insulin Resistance in Major Depressive Disorder</brief_title>
  <official_title>Role of Inflammation Factors and Insulin Resistance in the Pathophysiology and Treatment Response of Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cheng-Kung University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Science Council, Taiwan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cheng-Kung University Hospital</source>
  <oversight_info>
    <authority>Taiwan: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to identify evidence-based guidelines for treating major
      depressive disorder to full remission in Taiwanese major depressive disorder (MDD) patients.
      To achieve this goal, the investigators aim to: (1) evaluate the risks and benefits of
      adjunctive pharmacotherapies for cognitive and metabolic consequences in MDD, and (2)
      clarify the shared biological mechanisms between mood, immune and metabolism homeostasis
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Hamilton Depression Rating Scale (HDRS)</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>fasting plasma glucose</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fasting serum insulin</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive Protein, and IL-6</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Fluoxetine + Valsartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The initial dose of fluoxetine was 20 mg once daily, which could be increased by 20 mg in divided doses to a maximal daily dose of 60 mg.
Add-on treatment to 40 mg per day of valsartan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluoxetine + Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The initial dose of fluoxetine was 20 mg once daily, which could be increased by 20 mg in divided doses to a maximal daily dose of 60 mg.
Add-on treatment to placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluoxetine + Valsartan</intervention_name>
    <description>The curative effect of fluoxetine add-on valsartan 40 mg per day for 12 weeks therapy in the treatment of major depressive disorder.</description>
    <arm_group_label>Fluoxetine + Valsartan</arm_group_label>
    <other_name>Prozac</other_name>
    <other_name>Diovan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluoxetine + Placebo</intervention_name>
    <description>The curative effect of fluoxetine add-on placebo therapy in the treatment of major depressive disorder.</description>
    <arm_group_label>Fluoxetine + Placebo</arm_group_label>
    <other_name>Prozac</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 16-65 years old

          -  Signed informed consent by patient or legal representative

          -  Hamilton Rating Scale for Depression (HDRS) scores â‰¥ 16

          -  A diagnosis of MDD according to DSM-IV criteria made by a specialist in psychiatry

        Exclusion Criteria:

          -  Monoamine oxidase inhibitor or antidepressant treatment prior to entering the study

          -  A DSM-IV diagnosis of substance abuse within the past three months

          -  An organic mental disease, mental retardation or dementia

          -  A serious surgical condition or physical illness

          -  Patients who were pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Po See Chen, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cheng-Kung University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Po See Chen, M.D., Ph.D.</last_name>
    <phone>+886-6-2353535</phone>
    <phone_ext>5213</phone_ext>
    <email>chenps@mail.ncku.edu.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Psychiatry, National Cheng-Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <zip>701</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Po See Chen, M.D., Ph.D.</last_name>
      <phone>+886-6-2353535</phone>
      <phone_ext>5213</phone_ext>
      <email>chenps@mail.ncku.edu.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <lastchanged_date>October 2, 2012</lastchanged_date>
  <firstreceived_date>September 30, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cheng-Kung University Hospital</investigator_affiliation>
    <investigator_full_name>Po-See, Chen</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Major Depressive Disorder</keyword>
  <keyword>Antidepressants</keyword>
  <keyword>Insulin</keyword>
  <keyword>Fluoxetine</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fluoxetine</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Valsartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
